171 related articles for article (PubMed ID: 25318615)
21. The roles of integrin αvβ6 in cancer.
Niu J; Li Z
Cancer Lett; 2017 Sep; 403():128-137. PubMed ID: 28634043
[TBL] [Abstract][Full Text] [Related]
22. Ab initio molecular orbital calculations on specific interactions between urokinase-type plasminogen activator and its receptor.
Nagase K; Kobayashi H; Yoshikawa E; Kurita N
J Mol Graph Model; 2009 Aug; 28(1):46-53. PubMed ID: 19403319
[TBL] [Abstract][Full Text] [Related]
23. Downregulation of uPA/uPAR inhibits intermittent hypoxia-induced epithelial-mesenchymal transition (EMT) in DAOY and D283 medulloblastoma cells.
Gupta R; Chetty C; Bhoopathi P; Lakka S; Mohanam S; Rao JS; Dinh DE
Int J Oncol; 2011 Mar; 38(3):733-44. PubMed ID: 21181094
[TBL] [Abstract][Full Text] [Related]
24. Identification of specific sites involved in ligand binding by photoaffinity labeling of the receptor for the urokinase-type plasminogen activator. Residues located at equivalent positions in uPAR domains I and III participate in the assembly of a composite ligand-binding site.
Ploug M
Biochemistry; 1998 Nov; 37(47):16494-505. PubMed ID: 9843416
[TBL] [Abstract][Full Text] [Related]
25. Urokinase-type plasminogen activator binding to its receptor stimulates tumor cell migration by enhancing integrin-mediated signal transduction.
Yebra M; Goretzki L; Pfeifer M; Mueller BM
Exp Cell Res; 1999 Jul; 250(1):231-40. PubMed ID: 10388537
[TBL] [Abstract][Full Text] [Related]
26. Small molecule antagonists of the urokinase (uPA): urokinase receptor (uPAR) interaction with high reported potencies show only weak effects in cell-based competition assays employing the native uPAR ligand.
De Souza M; Matthews H; Lee JA; Ranson M; Kelso MJ
Bioorg Med Chem; 2011 Apr; 19(8):2549-56. PubMed ID: 21454081
[TBL] [Abstract][Full Text] [Related]
27. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
28. The uPA receptor and the somatomedin B region of vitronectin direct the localization of uPA to focal adhesions in microvessel endothelial cells.
Salasznyk RM; Zappala M; Zheng M; Yu L; Wilkins-Port C; McKeown-Longo PJ
Matrix Biol; 2007 Jun; 26(5):359-70. PubMed ID: 17344041
[TBL] [Abstract][Full Text] [Related]
29. Modulation of the urokinase-type plasminogen activator receptor by the beta6 integrin subunit.
Dalvi N; Thomas GJ; Marshall JF; Morgan M; Bass R; Ellis V; Speight PM; Whawell SA
Biochem Biophys Res Commun; 2004 Apr; 317(1):92-9. PubMed ID: 15047152
[TBL] [Abstract][Full Text] [Related]
30. Discovery of new small molecules targeting the vitronectin-binding site of the urokinase receptor that block cancer cell invasion.
Rea VE; Lavecchia A; Di Giovanni C; Rossi FW; Gorrasi A; Pesapane A; de Paulis A; Ragno P; Montuori N
Mol Cancer Ther; 2013 Aug; 12(8):1402-16. PubMed ID: 23699658
[TBL] [Abstract][Full Text] [Related]
31. Expression of urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor and maspin in oral squamous cell carcinoma: Association with mode of invasion and clinicopathological factors.
Yoshizawa K; Nozaki S; Kitahara H; Kato K; Noguchi N; Kawashiri S; Yamamoto E
Oncol Rep; 2011 Dec; 26(6):1555-60. PubMed ID: 21833477
[TBL] [Abstract][Full Text] [Related]
32. Discrimination of different forms of the murine urokinase plasminogen activator receptor on the cell surface using monoclonal antibodies.
Rasch MG; Pass J; Illemann M; Høyer-Hansen G; Lund IK
J Immunol Methods; 2008 Nov; 339(1):55-65. PubMed ID: 18761343
[TBL] [Abstract][Full Text] [Related]
33. Modulation of α
Ciregia F; Deroyer C; Cobraiville G; Plener Z; Malaise O; Gillet P; Fillet M; Malaise MG; de Seny D
Exp Mol Med; 2021 Feb; 53(2):210-222. PubMed ID: 33526813
[TBL] [Abstract][Full Text] [Related]
34. Structural analysis of the interaction between urokinase-type plasminogen activator and its receptor: a potential target for anti-invasive cancer therapy.
Ploug M; Gårdsvoll H; Jørgensen TJ; Lønborg Hansen L; Danø K
Biochem Soc Trans; 2002 Apr; 30(2):177-83. PubMed ID: 12023847
[TBL] [Abstract][Full Text] [Related]
35. Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).
Magdolen V; Bürgle M; de Prada NA; Schmiedeberg N; Riemer C; Schroeck F; Kellermann J; Degitz K; Wilhelm OG; Schmitt M; Kessler H
Biol Chem; 2001 Aug; 382(8):1197-205. PubMed ID: 11592401
[TBL] [Abstract][Full Text] [Related]
36. Interaction between cancer cells and stromal fibroblasts is required for activation of the uPAR-uPA-MMP-2 cascade in pancreatic cancer metastasis.
He Y; Liu XD; Chen ZY; Zhu J; Xiong Y; Li K; Dong JH; Li X
Clin Cancer Res; 2007 Jun; 13(11):3115-24. PubMed ID: 17545513
[TBL] [Abstract][Full Text] [Related]
37. Activation of urokinase receptor by a novel interaction between the connecting peptide region of urokinase and alpha v beta 5 integrin.
Franco P; Vocca I; Carriero MV; Alfano D; Cito L; Longanesi-Cattani I; Grieco P; Ossowski L; Stoppelli MP
J Cell Sci; 2006 Aug; 119(Pt 16):3424-34. PubMed ID: 16882693
[TBL] [Abstract][Full Text] [Related]
38. Urokinase receptor interacts with alpha(v)beta5 vitronectin receptor, promoting urokinase-dependent cell migration in breast cancer.
Carriero MV; Del Vecchio S; Capozzoli M; Franco P; Fontana L; Zannetti A; Botti G; D'Aiuto G; Salvatore M; Stoppelli MP
Cancer Res; 1999 Oct; 59(20):5307-14. PubMed ID: 10537314
[TBL] [Abstract][Full Text] [Related]
39. Expression of urokinase plasminogen activator and its receptor in advanced epithelial ovarian cancer patients.
Wang L; Madigan MC; Chen H; Liu F; Patterson KI; Beretov J; O'Brien PM; Li Y
Gynecol Oncol; 2009 Aug; 114(2):265-72. PubMed ID: 19450871
[TBL] [Abstract][Full Text] [Related]
40. Sheep (Ovis aries) integrins alphavbeta1 and alphavbeta6 related to foot-and-mouth disease virus infection: molecular cloning, sequence analysis and comparison with homologues.
Du J; Chang H; Gao S; Cong G; Shao J; Lin T; Liu Z; Liu X; Cai X
Mol Cell Probes; 2009 Oct; 23(5):247-57. PubMed ID: 19555755
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]